OP06 5-aminosalicylates are not associated with adverse outcomes in Inflammatory Bowel Disease patients with COVID-19: Analysis from an international registry

BACKGROUND: Prior data have suggested that 5-aminosalicylates (5-ASA) may be associated with an increased risk of severe COVID-19 among inflammatory bowel disease (IBD) patients. We aimed to evaluate the association of 5-ASA with severe COVID-19 in a large cohort of IBD patients. METHODS: We analyze...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Crohns Colitis
Main Authors: Ungaro, R, Brenner, E, Agrawal, M, Gearry, R B, Kaplan, G G, Kissous-Hunt, M, Ng, S C, Rahier, J F, Reinisch, W, Steinwurz, F, Zhang, X, Lewis, J D, Kappelman, M D, Colombel, J F
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Oral presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8194638/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjab075.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados